A

Alaunos Therapeutics Inc
NASDAQ:TCRT

Watchlist Manager
Alaunos Therapeutics Inc
NASDAQ:TCRT
Watchlist
Price: 3.1 USD -4.32%
Market Cap: 6.1m USD

Net Margin
Alaunos Therapeutics Inc

-40 710%
Current
-156 188.7%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-40 710%
=
Net Income
-4.1m
/
Revenue
10k

Net Margin Across Competitors

Alaunos Therapeutics Inc
Glance View

Market Cap
6.1m USD
Industry
Biotechnology

Alaunos Therapeutics, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. The company went IPO on 2004-08-20. The firm is focused on discovering, developing, and commercializing immuno-oncology platforms. The firm is engaged in developing technologies that utilize the immune system by employing innovative cell engineering to deliver cell therapies for the treatment of multiple cancer types. The company is focused on developing T-cell receptor (TCR), T cell therapies to target neoantigens in solid tumors (TCR-T). The firm's platform Sleeping Beauty is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that engineers T cells outside of the body for subsequent infusion. The company targets tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR, which are prevalent in gastrointestinal, lung, and gynecological cancers. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.

TCRT Intrinsic Value
0.06 USD
Overvaluation 98%
Intrinsic Value
Price
A
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-40 710%
=
Net Income
-4.1m
/
Revenue
10k
What is the Net Margin of Alaunos Therapeutics Inc?

Based on Alaunos Therapeutics Inc's most recent financial statements, the company has Net Margin of -40 710%.

Back to Top